Study of lung function test in association with laboratory findings of serum iron in patients with chronic obstructive pulmonary disease

Gothwal, Sunil; Palsaniya, Vikram; Barjatiya, Harish Chandra; Banseria, Ruchita; Sharma, Piyush; Goyal, Pramod; Ramaswamy, Vasudeva Murthy Challakere; Singh, Yogendra; Gupta, Gaurav

doi:10.1016/j.cegh.2022.101091

Cited by 1 publication

(1 citation statement)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Regardless of the data from previous studies revealing that the rest of the investigated blood biomarkers (e.g., ferritin, D-dimer, BNP, NLR, LDH) were associated with lung function impairment, we did not find any significant relationship between the aforementioned assays and pulmonary function measurements [9,[63][64][65][66]. However, that might be related to the small size of our study group.…”

Section: Blood Biomarkerscontrasting

confidence: 95%

Systemic Manifestations of COPD and the Impact of Dual Bronchodilation with Tiotropium/Olodaterol on Cardiac Function and Autonomic Integrity

Dimiene,

Hoppenot,

Vajauskas

et al. 2024

JCM

View full text Add to dashboard Cite

Background: Chronic obstructive pulmonary disease (COPD) has significant systemic manifestations, including cardiovascular morbidity. The main aim of our study was to evaluate the effect of short-term COPD treatment with tiotropium/olodaterol (TIO/OLO) 5/5 μg on cardiac function and autonomic integrity. Methods: Twenty-nine patients with newly diagnosed moderate-to-severe COPD were enrolled. We performed pulmonary function tests, cardiac magnetic resonance, cardiac 123I-metaiodobenzylguanidine (123I-MIBG) imaging and analysis of blood biomarkers on our study subjects. The correlations between the tests’ results were evaluated at baseline. The changes in pulmonary and cardiac parameters from baseline through 12 weeks were assessed. Results: Significant associations between pulmonary function tests’ results and high-sensitivity C-reactive protein (hs-CRP), as well as interleukin-22 (IL-22), were observed at baseline. Treatment with TIO/OLO significantly improved lung function as measured by spirometry and body plethysmography. Moreover, we found that the cardiac index increased from 2.89 (interquartile range (IQR) 1.09) to 3.21 L/min/m2 (IQR 0.78) (p = 0.013; N = 18) and the late heart-to-mediastinum ratio improved from 1.88 (IQR 0.37) to 2 (IQR 0.41) (p = 0.026; N = 16) after 12 weeks of treatment. Conclusions: Treatment with TIO/OLO improves lung function and positively impacts cardiac function and autonomic integrity, suggesting that dual bronchodilation might have a potential in decreasing the risk for cardiac events in COPD. Hs-CRP and IL-22 might be beneficial in determining the intensity of systemic inflammation in COPD. Further research with a larger cohort is needed to enhance the initial results of this study.

show abstract